Viewing Study NCT01276366


Ignite Creation Date: 2025-12-24 @ 3:59 PM
Ignite Modification Date: 2025-12-29 @ 6:28 AM
Study NCT ID: NCT01276366
Status: COMPLETED
Last Update Posted: 2019-01-17
First Post: 2010-04-23
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Amphia Premature Infant Pain Study
Sponsor: Amphia Hospital
Organization:

Study Overview

Official Title: Amphia Premature Infant Pain Study; Breast Milk vs Sucrose
Status: COMPLETED
Status Verified Date: 2019-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: APIP
Brief Summary: Last thirty years, many research was performed concerning pain in the newborn. These investigations showed us the negative effects of pain in the neonatal period. Our research concerns the choice of analgesics for the premature newborn during a heel lance. Newborns with a gestational age of 32-37 weeks are randomly assigned over three groups. They can receive breastfeeding, during the heel lance, a bottle with supplemental breast milk or sucrose.

The primary objective of the Amphia Premature Infant Pain study, is to investigate whether there is a difference in PIPP-scores in premature newborns who undergo a heel lance, receiving breast milk or sucrose. Our hypothesis is that the PIPP-score will be lower in newborns receiving breast milk compared to sucrose. And the investigators presume that breast feeding has the same analgesic effect as giving supplemental breast milk.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: